Results 111 to 120 of about 15,810 (189)

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa

open access: yes
Methods: The study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016-22) who received ceftolozane/tazobactam or ceftazidime/avibactam within 3 days of index culture for ≥2 days.
Obi, Engels N.   +5 more
core   +1 more source

<i>In vivo</i> efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant <i>Pseudomonas aeruginosa</i> carrying the AmpC E219K substitution. [PDF]

open access: yesAntimicrob Agents Chemother
Rodríguez-Coello A   +14 more
europepmc   +1 more source

Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations. [PDF]

open access: yesAntibiotics (Basel)
Yücel E   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy